Evidence map›Paper›PMID 22690114›Full record

ArticleMolecular vision2012

A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs.

Moutushy Mitra, Chandana Mohanty, Anju Harilal, Uma K Maheswari, Sanjeeb Kumar Sahoo, Subramanian Krishnakumar

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. In Vitro Models of Biological Barriers for Nanomedical Research.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Looking for In Vitro Models for Retinal Diseases.International journal of molecular sciences · 2021
    Review
  6. Review
  7. Consistent Inclusion of Mesenchymal Stem Cells into In Vitro Tumor Models.Methods in molecular biology (Clifton, N.J.) · 2021
    Review
  8. Review
  9. Article
  10. Expression profiles and prognostic value of miRNAs in retinoblastoma.Journal of cancer research and clinical oncology · 2019
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. 3D tissue-engineered model of Ewing's sarcoma.Advanced drug delivery reviews · 2014
    Review
  16. A microphysiological system model of therapy for liver micrometastases.Experimental biology and medicine (Maywood, N.J.) · 2014
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Moutushy MitraDepartment of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Chandana Mohanty
Anju Harilal
Uma K Maheswari
Sanjeeb Kumar Sahoo
Subramanian Krishnakumar
Sankara Nethralaya · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNovel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable, polymeric microparticles as a scaffold for three dimensional (3-D) growth of a Y79 retinoblastoma (RB) cell line. We evaluated the effect of three anticancer drugs in naïve and nanoparticle-loaded forms on a 3-D versus a two-dimensional (2-D) model. We also studied the influence of microparticles on extracellular matrix (ECM) synthesis and whole genome miRNA-gene expression profiling to identify 3D-responsive genes that are implicated in oncogenesis in RB cells.

methodsPoly(D,L)-lactide-co-glycolide (PLGA) microparticles were prepared by the solvent evaporation method. RB cell line Y79 was grown alone or with PLGA-gelatin microparticles. Antiproliferative activity, drug diffusion, and cellular uptake were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay, fluorescent microscope, and flow cytometry. Extra cellular matrix (ECM) synthesis was observed by collagenase assay and whole genome miRNA-microarray profiling by using an Agilent chip.

resultsWith optimized composition of microparticles and cell culture conditions, an eightfold increase from the seeding density was achieved in 5 days of culture. The antiproliferative effect of the drugs in the 3-D model was significantly lower than in the 2-D suspension, which was evident from the 4.5 to 21.8 fold differences in their IC(50) values. Using doxorubicin, the flow cytometry data demonstrated a 4.4 fold lower drug accumulation in the cells grown in the 3-D model at 4 h. The collagen content of the cells grown in the 3-D model was 2.3 fold greater than that of the cells grown in the 2-D model, suggesting greater synthesis of the extracellular matrix in the 3-D model as the extracellular matrix acted as a barrier to drug diffusion. The microarray and miRNA analysis showed changes in several genes and miRNA expression in cells grown in the 3-D model, which could also influence the environment and drug effects.

conclusionsOur 3-D retinoblastoma model could be used in developing effective drugs based on a better understanding of the role of chemical, biologic, and physical parameters in the process of drug diffusion through the tumor mass, drug retention, and therapeutic outcome.

Indexed as

Antineoplastic AgentsBiocompatible MaterialsCarboplatinCell Culture TechniquesCell ProliferationCell SurvivalDiffusionDoxorubicinEtoposideExtracellular MatrixGene Expression ProfilingHumansInhibitory Concentration 50KineticsLactic AcidMicroRNAsAntineoplastic AgentsBiocompatible MaterialsCarboplatinDoxorubicinEtoposideLactic AcidMicroRNAsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymer

Identifiers

PMID22690114
PMCPMC3369889
OpenAlexW2158895086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.